WO2009056551A1 - Dérivés de furo[3,2-d]pyrimidine - Google Patents

Dérivés de furo[3,2-d]pyrimidine Download PDF

Info

Publication number
WO2009056551A1
WO2009056551A1 PCT/EP2008/064622 EP2008064622W WO2009056551A1 WO 2009056551 A1 WO2009056551 A1 WO 2009056551A1 EP 2008064622 W EP2008064622 W EP 2008064622W WO 2009056551 A1 WO2009056551 A1 WO 2009056551A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
atom
alkyl
heterocyclic group
compounds
Prior art date
Application number
PCT/EP2008/064622
Other languages
English (en)
Inventor
Elena CARCELLER GONZÁLEZ
Eva María MEDINA FUENTES
Josep MARTÍ VIA
Marina VIRGILI BERNADÓ
Original Assignee
Palau Pharma, S. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palau Pharma, S. A. filed Critical Palau Pharma, S. A.
Publication of WO2009056551A1 publication Critical patent/WO2009056551A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Dérivés de furo[3,2-d]pyrimidine de formule I, dans lesquels les significations pour les divers substituants sont telles que définies dans la description. Ces composés sont utiles en tant qu'antagonistes du récepteur H4.
PCT/EP2008/064622 2007-10-30 2008-10-28 Dérivés de furo[3,2-d]pyrimidine WO2009056551A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07381071 2007-10-30
EP07381071.5 2007-10-30
US1993708P 2008-01-09 2008-01-09
US61/019,937 2008-01-09

Publications (1)

Publication Number Publication Date
WO2009056551A1 true WO2009056551A1 (fr) 2009-05-07

Family

ID=39217961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/064622 WO2009056551A1 (fr) 2007-10-30 2008-10-28 Dérivés de furo[3,2-d]pyrimidine

Country Status (4)

Country Link
AR (1) AR069113A1 (fr)
PE (1) PE20090978A1 (fr)
TW (1) TW200934783A (fr)
WO (1) WO2009056551A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010072829A1 (fr) 2008-12-24 2010-07-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes sélectifs du récepteur h4 de l'histamine dans le traitement de troubles vestibulaires
WO2013008162A1 (fr) 2011-07-08 2013-01-17 Novartis Ag Nouveaux dérivés de trifluorométhyl-oxadiazole et leur utilisation pour le traitement de maladies
WO2013182711A1 (fr) 2012-06-08 2013-12-12 Sensorion Inhibiteurs des récepteurs h4 pour le traitement des acouphènes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050965A1 (fr) * 2004-11-11 2006-05-18 Argenta Discovery Ltd Composes pyrimidine utilises comme modulateurs de l'histamine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050965A1 (fr) * 2004-11-11 2006-05-18 Argenta Discovery Ltd Composes pyrimidine utilises comme modulateurs de l'histamine

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010072829A1 (fr) 2008-12-24 2010-07-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes sélectifs du récepteur h4 de l'histamine dans le traitement de troubles vestibulaires
US9526725B2 (en) 2008-12-24 2016-12-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Selective histamine H4 receptor antagonists for the treatment of vestibular disorders
US10195195B2 (en) 2008-12-24 2019-02-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Selective histamine H4 receptor antagonists for the treatment of vestibular disorders
WO2013008162A1 (fr) 2011-07-08 2013-01-17 Novartis Ag Nouveaux dérivés de trifluorométhyl-oxadiazole et leur utilisation pour le traitement de maladies
WO2013182711A1 (fr) 2012-06-08 2013-12-12 Sensorion Inhibiteurs des récepteurs h4 pour le traitement des acouphènes
US9688989B2 (en) 2012-06-08 2017-06-27 Sensorion H4 receptor inhibitors for treating tinnitus
EP3378476A1 (fr) 2012-06-08 2018-09-26 Sensorion Inhibiteurs du récepteur h4 destinés au traitement des acouphènes

Also Published As

Publication number Publication date
AR069113A1 (es) 2009-12-30
PE20090978A1 (es) 2009-07-13
TW200934783A (en) 2009-08-16

Similar Documents

Publication Publication Date Title
ES2735750T3 (es) Derivados de imidazol y pirazol condensados como moduladores de la actividad de TNF
WO2009068512A1 (fr) Dérivés de 2-aminopyrimidine en tant qu'antagonistes d'histamine h4
EP2235012B1 (fr) Dérivés de 4-aminopyrimidine antagonistes du récepteur histamine h4
KR102268155B1 (ko) 테트라히드로피라졸로피리미딘 화합물
WO2009077608A1 (fr) Dérivés de 2-aminopyrimidine comme antagonistes des récepteurs h4 de l'histamine
WO2014173291A1 (fr) Composés diaminopyrimidines deutériés, et compositions pharmaceutiques comprenant ces composés
WO2007031529A1 (fr) Dérivés de 2-aminopyrimidine en tant que modulateurs de l'activité du récepteur h4 de l'histamine
AU2014309788A1 (en) Novel quinoline-substituted compound
WO2018218051A1 (fr) Inhibiteurs de kinase 1 de régulation du signal apoptotique, et leurs méthodes d'utilisation
MX2014009991A (es) Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.
AU2022312986A1 (en) Annulated pyridazine compound
WO2009056551A1 (fr) Dérivés de furo[3,2-d]pyrimidine
WO2009115496A1 (fr) Dérivés de la furo[3,2-d]pyrimidine en tant qu'antagonistes des récepteurs de h4
KR20170024026A (ko) 트리사이클릭 트리아졸릭 화합물
WO2010043633A1 (fr) Dérivés de 2h-pyrazolo[4,3-d]pyrimidin-5-amine utilisés comme antagonistes des récepteurs h4 de l'histamine pour le traitement de maladies allergiques, immunologiques et inflammatoires
WO2010094721A1 (fr) Dérivés de pipéridine-pyrimidine comme antagonistes des récepteurs histaminiques h4
KR102242405B1 (ko) 시그마 수용체 리간드로서의 트리사이클릭 트리아졸릭 화합물
WO2023155900A1 (fr) Composé hétérocyclique à cinq chaînons et à six chaînons, et son utilisation en tant qu'inhibiteur de protéine kinase
KR20230118921A (ko) H4 길항제 화합물
TW202411229A (zh) 用於治療發炎性病症之新穎化合物及其醫藥組合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08843487

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08843487

Country of ref document: EP

Kind code of ref document: A1